Gene polymorphisms involved in triptans pharmacokinetics and pharmacodynamics in migraine therapy

Bibliography

• Wessman M, Terwindt GM, Kaunisto MA, Migraine: a complex genetic disorder. Lancet Neurol 2007;6:521-32
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Charbit AR, Andreou AP, Neurobiology of migraine. Neuroscience 2009;161:327-41
   PubMed Web of Science ®Google Scholar
• Aguggia M, Saracco MG. Pathophysiology of migraine chronification. Neurol Sci 2010:31(Suppl 1):S15-17
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Saxena PR. On serotonin and migraine: a clinical and pharmacological review. Cephalalgia 1993;13(3):151-65
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Serotonin (5HT) and migraine. Headache 1994;34(7):408-17
   PubMed Web of Science ®Google Scholar
• Akerman S, Goadsby PJ. Dopamine and migraine: biology and clinical implications. Cephalalgia 2007;27(11):1308-14
   PubMed Web of Science ®Google Scholar
• Humphrey PP, Feniuk W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci 1991;12:444-6
   PubMed Web of Science ®Google Scholar
• Humphrey PP. The discovery of a new drug class for the acute treatment of migraine. Headache 2007;47(Suppl 1):S10-19
   PubMed Web of Science ®Google Scholar
• Bigal ME, Krymchantowski AV, Ho T. Migraine in the triptan era. Arq Neuropsiquiatr 2009;67(2B):559-69
   PubMed Web of Science ®Google Scholar
• Levy D, Jakubowski M, Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc Natl Acad Sci USA 2004;101:4274-9
   PubMed Web of Science ®Google Scholar
• Hartig PR, Hoyer D, Humphrey PPA, Alignment of receptor nomenclature with the human genome: Classification of 5HT1B and 5HT1D receptor subtypes. Trends Pharmacol Sci 1996;17:103-5
   PubMed Web of Science ®Google Scholar
• Hoyer D, Clarke DE, Fozard JR, International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994;46:157-203
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Lipton RB, Ferrari MD. Migraine – current understanding and treatment. N Engl J Med 2002;346(4):257-70
   PubMed Web of Science ®Google Scholar
• Belvis R, Pagonabarraga J, Kulisevsky J. Individual triptan selection in migraine attack therapy. Recent Pat CNS Drug Discov 2009;4:70-81
   PubMedGoogle Scholar
• Rapoport AM, Tepper SJ, Sheftell FD, Which triptan for which patient? Neurol Sci 2006;27(Suppl 2):S123-9
   PubMed Web of Science ®Google Scholar
• Jhee SS, Shiovitz T, Crawford AW, Cutler NR. Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet 2001;40:189-205
   PubMed Web of Science ®Google Scholar
• Dixon CM, Park GR, Tarbit MH. Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver. Biochem Pharmacol 1994;47:1253-7
   PubMed Web of Science ®Google Scholar
• Van Haarst AD, Van Gerven JM, Cohen AF, The effects of moclobemide on the pharmacokinetics of the 5HT1B/1D agonist rizatriptan in healthy volunteers. Br J Clin Pharmacol 1999;48:190-6
   PubMed Web of Science ®Google Scholar
• Salva M, Jansat JM, Martinez-Tobed A, Palacios JM. Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos 2003;31:404-11
   PubMed Web of Science ®Google Scholar
• Dixon R, French S, Kemp J, The metabolism of zolmitriptan: effects of an inducer and an inhibitor of cytochrome p450 on its pharmacokinetics in healthy volunteers. Clin Drug Investig 1998;15:515-22
   PubMed Web of Science ®Google Scholar
• Rolan P. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90). Cephalalgia 1997;17(Suppl 18):21-7
   PubMed Web of Science ®Google Scholar
• Takiya L, Piccininni LC, Kamath V. Safety and efficacy of eletriptan in the treatment of acute migraine. Pharmacotherapy 2006;26:115-28
   PubMed Web of Science ®Google Scholar
• Buchan P, Wade A, Ward C, Frovatriptan: a review of drug-drug interactions. Headache 2002;42(Suppl 2):S63-73
   PubMed Web of Science ®Google Scholar
• Ferrari A, Sternieri E, Ferraris E, Emerging problems in the pharmacology of migraine: interactions between triptans and drugs for prophylaxis. Pharmacol Res 2003;48:1-9
   PubMed Web of Science ®Google Scholar
• Loder E. Triptan therapy in migraine. N Engl J Med 2010;363:63-70
   PubMed Web of Science ®Google Scholar
• Simmaco M, Borro M, Missori S, Pharmacogenomics in migrane: catching biomarkers for a predictable disease control. Expert Rev Neurother 2009;9(9):1267-9
   PubMed Web of Science ®Google Scholar
• Stefulj J, Bordukalo-Niksic T, Hecimovic H, Epilepsy and serotonin (5HT): variations of 5HT-related genes in temporal lobe epilepsy. Neurosci Lett 2010;478(1):29-31
   PubMed Web of Science ®Google Scholar
• Guimaraes AP, Schmitz M, Polanczyk GV, Further evidence for the association between attention deficit/hyperactivity disorder and the serotonin receptor 1B gene. J Neural Transm 2009;116(12):1675-80
   PubMed Web of Science ®Google Scholar
• Kim SJ, Namkoong K, Kang JI, Association of a 5HT1Dbeta receptor gene polymorphism with obsessive-compulsive disorder in Korean male subjects. Neuropsychobiology 2009;59(2):96-9
   PubMed Web of Science ®Google Scholar
• Duan J, Sanders AR, Molen JE, Polymorphisms in the 5′-untranslated region of the human serotonin receptor 1B (HTR1B) gene affect gene expression. Mol Psychiatry 2003;8(11):901-10
   PubMed Web of Science ®Google Scholar
• Lappalainen J, Long JC, Eggert M, Linkage of antisocial alcoholism to the serotonin 5HT1B receptor gene in 2 populations. Arch Gen Psychiatry 1998;55:989-94
   PubMed Web of Science ®Google Scholar
• Hasegawa Y, Higuchi S, Matsushita S, Miyaoka H. Association of a polymorphism of the serotonin 1B receptor gene and alcohol dependence with inactive aldehyde dehydrogenase-2. J Neural Transm 2002;09:513-21
   Web of Science ®Google Scholar
• New AS, Gelernter J, Goodman M, Suicide, impulsive aggression, and HTR1B genotype. Biol Psychiatry 2001;50:62-5
   PubMed Web of Science ®Google Scholar
• MaassenVanDenBrink A, Vergouwe MN, Ophoff RA, 5HT1B Receptor Polymorphism and Clinical Response to Sumatriptan. Headache 1998;38:288-91
   PubMed Web of Science ®Google Scholar
• Bruss M, Bonisch H, Buhlen M, Modified ligand binding to the naturally occurring Cys-124 variant of the human serotonin 5HT1B receptor. Pharmacogenetics 1999;9(1):95-102
   PubMedGoogle Scholar
• Mehrotra S, Vanmolkot KR, Frants RR, The phe-124-Cys and A-161T variants of the human 5HT1B receptor gene are not major determinants of the clinical response to sumatriptan. Headache 2007;47(5):711-16
   PubMed Web of Science ®Google Scholar
• Asuni C, Cherchi A, Congiu D, Association study between clinical response to rizatriptan and some candidate genes. J Headache Pain 2007;8(3):185-9
   PubMed Web of Science ®Google Scholar
• Velati D, Viana M, Cresta S, 5-hydroxytryptamine1B receptor and triptan response in migraine, lack of association with common polymorphisms. Eur J Pharmacol 2008;580(1-2):43-7
   PubMed Web of Science ®Google Scholar
• Moss HB, Hardie TL, Dahl JP, Diplotypes of the human serotonin 1B receptor promoter predict growth hormone responses to sumatriptan in abstinent alcohol-dependent men. Biol Psychiatry 2007;61(8):974-8
   PubMed Web of Science ®Google Scholar
• MaassenVanDenBrink A, Vergouwe MN, Ophoff RA, Chromosomal localization of the 5HT1F receptor gene: no evidence for involvement in response to sumatriptan in migraine patients. Am J Med Genet 1998;77:415-20
   PubMed Web of Science ®Google Scholar
• Lesch KP, Mossner R. Genetically driven variation in serotonin uptake: is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders? Biol Psychiatry 1998;44:179-92
   PubMed Web of Science ®Google Scholar
• Lesch KP, Bengel D, Heils A, Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996;274:1527-31
   PubMed Web of Science ®Google Scholar
• Fiskerstrand CE, Lovejoy EA, Quinn JP. An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells. FEBS Lett 1999;458:171-4
   PubMed Web of Science ®Google Scholar
• Smits KM, Smits LJ, Peeters FP, The influence of 5HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients. Psychiatr Genet 2008;18:184-90
   PubMed Web of Science ®Google Scholar
• Sarosi A, Gond X, Balogh G, Association of the STin2 polymorphism of the serotonin transporter gene with a neurocognitive endophenotype in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1667-72
   PubMed Web of Science ®Google Scholar
• Zalsman G, Huang YY, Oquendo MA, Association of a triallelic serotonin transporter gene promoter region (5HTTLPR) polymorphism with stressful life events and severity of depression. Am J Psychiatry 2006;163:1588-93
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Block G, Dahlof C, Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000;20:765-86
   PubMed Web of Science ®Google Scholar
• Terrazzino S, Viana M, Floriddia E, The serotonin transporter gene polymorphism STin2 VNTR confers an increased risk of inconsistent response to triptans in migraine patients. Eur J Pharmacol 2010;641(2-3):82-7
   PubMed Web of Science ®Google Scholar
• Siffert W, Rosskopf D, Siffert G, Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet 1998;18:45-8
   PubMed Web of Science ®Google Scholar
• Schurks M, Kurth T, Stude P, G protein beta3 polymorphism and triptan response in cluster headache. Clin Pharmacol Ther 2007;82:396-401
   PubMed Web of Science ®Google Scholar
• Gentile G, Borro M, Lala N, Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine. J Headache Pain 2010;11:431-5
   PubMed Web of Science ®Google Scholar
• Mascia A, Afra J, Schoenen J. Dopamine and migraine: a review of pharmacological, biochemical, neurophysiological, and therapeutic data. Cephalalgia 1998;18:174-82
   PubMed Web of Science ®Google Scholar
• Todt U, Netzer C, Toliat M, Hum Genet 2009;125:265-79
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Breakefield XO. Human monoamine oxidase A gene determines levels of enzyme activity. Am J Hum Genet 1991;49(2):383-92
   PubMed Web of Science ®Google Scholar
• Sabol SZ, Hu S, Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet 1998;103(3):273-9
   PubMed Web of Science ®Google Scholar
• Corominas R, Sobrido MJ, Ribases M. Association study of the serotoninergic system in migraine in the Spanish population. Am J Med Genet B Neuropsychiatr Genet 2010;153B(1):177-84
   PubMed Web of Science ®Google Scholar
• Filic V, Vladic A, Stefulj J, Monoamine oxidases A and B gene polymorphisms in migraine patients. J Neurol Sci 2005;228(2):149-53
   PubMed Web of Science ®Google Scholar
• Gentile G, Missori S, Borro M, Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine. J Headache Pain 2010;11(2):151-6
   PubMed Web of Science ®Google Scholar
• Omari AA, Murry DJ. Pharmacogenetics of the Cytochrome P450 enzyme system: review of current knowledge and clinical significance. J Pharm Pract 2007;20:206-16
   Google Scholar
• Zhou SF, Yang LP, Zhou ZW, Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J 2009;11(3):481-94
   PubMed Web of Science ®Google Scholar
• Stovner LJ, Tronvik E, Hagen H. New drugs for migraine. J Headache Pain 2009;10:395-406
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P. What can be learned from the history of recurrence of migraine? A comment. J Headache Pain 2009;10:311-15
   PubMed Web of Science ®Google Scholar
• Bozina N, Bradamante V, Lovric M. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh Hig Rada Toksikol 2009;60(2):217-42
   PubMed Web of Science ®Google Scholar
• Leucuta SE, Vlase L. Pharmacokinetics and metabolic drug interactions. Curr Clin Pharmacol 2006;1(1):5-20
   PubMedGoogle Scholar
• Schurks M, Rist PM, Kurth T. STin2 VNTR polymorphism in the serotonin transporter gene and migraine: pooled and meta-analyses. J Headache Pain 2010;11(4):317-26
   PubMed Web of Science ®Google Scholar
• Evans DC, O'Connor D, Lake BG, Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos 2003;31(7):861-9
   PubMed Web of Science ®Google Scholar
• Gupta R, Kumar V, Luthra K. Polymorphism in apolipoprotein E among migraineurs and tension-type headache subjects. J Headache Pain 2009;10(2):115-20
   PubMed Web of Science ®Google Scholar
• Cevoli S, Marzocchi N, Capellari S, Lack of association between five serotonin metabolism-related genes and medication overuse headache. J Headache Pain 2010;11(1):53-8
   PubMed Web of Science ®Google Scholar